drugset / Trial / NCT05841381
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open label, phase III study evaluating the efficacy and safety of Pyrotinib in Combination With Trastuzumab and paclitaxel in patients HER2 Positive and lymph node negative invasive Breast Cancer
Timeline
- Start
- 2023-05-06
- Primary completion
- 2028-05-06
- Completion
- 2033-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyrotinib | Small molecule | 400 mg | Oral |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Background | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |